1. Home
  2. Live Updates
  3. Joshuak sabari

Live Breaking News & Updates on Joshuak sabari

Stay informed with the latest breaking news from Joshuak sabari on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Joshuak sabari and stay connected to the pulse of your community

Dr Sabari on the FDA Approval of Frontline Amivantamab Plus Chemo in EGFR Exon 20 Insertion+ NSCLC

Joshua K. Sabari, MD, discusses the FDA approval of frontline amivantamab plus chemotherapy for NSCLC harboring EGFR exon 20 insertion mutations.

United-states , Joshuak-sabari , York-university-grossman-school-of-medicine , Department-of-medicine , New-york-university-grossman-school ,

Breaking Boundaries: Advancements and Challenges in Treatment with ADCs in NSCLC

Joshua K. Sabari, MD, discusses updates in ADCs in NSCLC.

Joshuak-sabari , Department-of-medicine-at-new-york-university , Grossman-school-of-medicine , Langone-health , New-york-university , Grossman-school , High-reliability-organization-initiatives , Perlmutter-cancer-center , Adc , Nsclc , D

Unlocking the Potential: The Evolution of ADCs in HER2+ NSCLC

Joshua K. Sabari, MD, explains the utility of ADCs in patients with NSCLC and their benefit in patients with EGFR-, ALK-, or HER2-mutant disease.

Joshuak-sabari , Grossman-school-of-medicine , Department-of-medicine-at-new-york-university , Langone-health , New-york-university , Grossman-school , High-reliability-organization-initiatives , Perlmutter-cancer-center , Lung-cancer , Adcs , Nsclc

State of the Science Summit - Lung Cancer: Chaired by Joshua K Sabari, MD

State of the Science Summit - Lung Cancer: Chaired by Joshua K Sabari, MD

Joshuak-sabari , Salmanr-punekar , Joshua-sabari , Perlmutter-cancer-center , Langone-health , Science-summit , Science-summits , Institutional-perspectives , Breast-cancer , Lung-cancer , Onclive-on-air , D

Treatment Options in EGFR-Mutant NSCLC in Second Line and Beyond

Joshua K. Sabari, MD, reviews data from the MARIPOSA-2 trial and discusses treatment options in the second line and beyond for patients with EGFR-mutant non–small cell lung cancer.

Joshuak-sabari , Evolving-treatment-paradigm , Advanced-non , Small-cell-lung-cancer , Second-line , Non-small-cell-lung-cancer , Nsclc , Advanced-non-small-cell-lung-cancer , Advanced-nsclc , Nsclc-treatment , Egfr-mutant-lung-cancer

TROPION-Lung04: Dato-DXd Plus Immunotherapy in Advanced NSCLC

Joshua K. Sabari, MD, reviews data from the TROPION-Lung04 study, and the panel offers key takeaways on Dato-DXd and immunotherapy in advanced NSCLC.

Joshuak-sabari , Evolving-treatment-paradigm , Advanced-non , Small-cell-lung-cancer , Non-small-cell-lung-cancer , Nsclc , Advanced-non-small-cell-lung-cancer , Advanced-nsclc , Nsclc-treatment , Adc , Antibody-drug-conjugate

Dr Sabari on Gene Mutations and Fusions in Lung Cancer

Joshua K. Sabari, MD, discusses gene mutations and fusions in the context of lung cancer.

Joshuak-sabari , Langone-health-perlmutter-cancer-center , Grossman-school-of-medicine , Department-of-medicine , Perlmutter-cancer-center ,

LY3537982 Demonstrates Tolerability and Preliminary Efficacy in KRAS G12C–mutated Advanced Solid Tumors

Joshua K. Sabari, MD, shares how the unique pharmacokinetics and mechanism of action for LY3537982 supported its investigation in the LOXO-RAS- 20001 study, findings presented at AACR, and how this research could address unmet needs in patients with KRAS G12C–mutant solid tumors.

New-york , United-states , Joshuak-sabari , Department-of-medicine , Grossman-school-of-medicine , Langone-health-perlmutter-cancer-center , Perlmutter-cancer-center , Mechanism-of-action-for-ly3537982 , Loxo-ras-20001-study , Aacr , Patients-with-kras-g12c-mutant-solid-tumors

Dr Sabari on Preliminary Data From a Phase 1 Study of LY3537982 in KRAS G12C–mutant Advanced Solid Tumors

Joshua K. Sabari, MD, discusses key findings from the phase 1 LOXO-RAS-20001 study of the KRAS G12C inhibitor LY3537982 in KRAS G12C–mutant advanced solid tumors.



Joshuak-sabari , Grossman-school-of-medicine , Langone-health-perlmutter-cancer-center , Department-of-medicine , Perlmutter-cancer-center , Non-small-cell-lung-cancer , Ly3537982 , Phase-1-loxo-ras-20001-study-nct04956640- , Kras-g12c-inhibitor- , Kras-g12c-mutant-advanced-solid-tumors ,

Mirati Therapeutics to Present New Research at the 2022 ASCO Annual Meeting Showcasing Clinical Advances of Treating KRASG12C-Mutated Lung Cancer with Investigational Adagrasib

/PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX), a clinical-stage targeted oncology company today announced the presentation of new clinical research...

United-states , Chicago , Illinois , American , Charles-baum , Joshuak-sabari , Alexanderi-spira , Linkedin , American-society-of-clinical-oncology , Twitter , Prnewswire-mirati-therapeutics-inc , Drug-administration